Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Receivables (2019 - 2025)

Benitec Biopharma has reported Receivables over the past 7 years, most recently at $130000.0 for Q4 2025.

  • Quarterly results put Receivables at $130000.0 for Q4 2025, up 6400.0% from a year ago — trailing twelve months through Dec 2025 was $130000.0 (up 6400.0% YoY), and the annual figure for FY2025 was $33000.0, down 85.59%.
  • Receivables reached $130000.0 in Q4 2025 per BNTC's latest filing, up from $7000.0 in the prior quarter.
  • Across five years, Receivables topped out at $229000.0 in Q2 2024 and bottomed at $2000.0 in Q4 2024.
  • Median Receivables over the past 5 years was $17500.0 (2021), compared with a mean of $40000.0.
  • The largest annual shift saw Receivables tumbled 96.23% in 2024 before it skyrocketed 6400.0% in 2025.
  • Over 5 years, Receivables stood at $5000.0 in 2021, then soared by 1260.0% to $68000.0 in 2022, then dropped by 22.06% to $53000.0 in 2023, then crashed by 96.23% to $2000.0 in 2024, then surged by 6400.0% to $130000.0 in 2025.
  • Business Quant data shows Receivables for BNTC at $130000.0 in Q4 2025, $7000.0 in Q3 2025, and $33000.0 in Q2 2025.